{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:25:59Z","timestamp":1794536759173,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with lung cancer who are treated with carboplatin-based chemotherapy regimens often experience chemotherapy-induced nausea and vomiting (CINV). However, knowledge on the effect of regimen and cofactors on the risk of CINV is limited. This study aimed to analyze and compare the incidence of CINV between lung cancer patients undergoing carboplatin plus pemetrexed (CBDCA+PEM) and those undergoing carboplatin plus paclitaxel (CBDCA+PTX) chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Pooled data of 240 patients from two prospective observational studies were compared using propensity score matching. Separate multivariate logistic regression analyses were used to identify risk factors for nausea and vomiting following chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Delayed nausea was significantly more common in patients treated with CBDCA+PEM than in those treated with CBDCA+PTX (51.1% vs. 36.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.04), but the incidence of vomiting did not significantly differ between the two groups (23.4% vs. 14.9%, <jats:italic>P<\/jats:italic>\u2009=\u20090.14). The occurrence of CINV peaked on day 4 in the CBDCA+PTX group and on day 5 in the CBDCA+PEM group. Multivariate analysis showed that female sex, younger age, and CBDCA+PEM regimen were independent risk factors for delayed nausea, while female sex was an independent risk factor for delayed vomiting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The CBDCA + PEM regimen has a higher risk of causing delayed nausea than the CBDCA + PTX regimen, and aggressive antiemetic prophylaxis should be offered to patients treated with CBDCA + PEM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-07802-y","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T19:02:36Z","timestamp":1610737356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-4939","authenticated-orcid":false,"given":"Toshinobu","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"7802_CR1","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/jco.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35:3240\u201361. https:\/\/doi.org\/10.1200\/jco.2017.74.4789.","journal-title":"J Clin Oncol"},{"key":"7802_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00520-016-3365-1","volume":"25","author":"F Roila","year":"2017","unstructured":"Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, et al. B. 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer. 2017;25:289\u201394. https:\/\/doi.org\/10.1007\/s00520-016-3365-1.","journal-title":"Support Care Cancer"},{"key":"7802_CR3","volume-title":"Antiemetics. Version 1, 2019","author":"NCCN clinical practice guidelines in oncology","year":"2019","unstructured":"NCCN clinical practice guidelines in oncology (2019) Antiemetics. Version 1, 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 30 July 2019."},{"key":"7802_CR4","volume-title":"Version 2.2","author":"JSCO guidelines for antiemetics in oncology 2015","year":"2018","unstructured":"JSCO guidelines for antiemetics in oncology 2015. Version 2.2, 2018. http:\/\/www.jsco-pg.jp\/item\/29\/index.html. Accessed 30 July 2019."},{"key":"7802_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00520-016-3332-x","volume":"25","author":"K Jordan","year":"2017","unstructured":"Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, Hesketh PJ. 2016 updated MASCC\/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer. 2017;25:271\u20135. https:\/\/doi.org\/10.1007\/s00520-016-3332-x.","journal-title":"Support Care Cancer"},{"key":"7802_CR6","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/cncr.30054","volume":"122","author":"PJ Hesketh","year":"2016","unstructured":"Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, et al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer. 2016;122:2418\u201325. https:\/\/doi.org\/10.1002\/cncr.30054.","journal-title":"Cancer"},{"key":"7802_CR7","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00520-018-4242-x","volume":"26","author":"C Weinstein","year":"2018","unstructured":"Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, et al. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. Support Care Cancer. 2018;26:3773\u201380. https:\/\/doi.org\/10.1007\/s00520-018-4242-x.","journal-title":"Support Care Cancer"},{"key":"7802_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","volume":"84","author":"Y Ito","year":"2014","unstructured":"Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y, et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer. 2014;84:259\u201364. https:\/\/doi.org\/10.1016\/j.lungcan.2014.03.017.","journal-title":"Lung Cancer"},{"key":"7802_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","volume":"90","author":"H Kusagaya","year":"2015","unstructured":"Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, et al. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer. 2015;90:410\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2015.11.009.","journal-title":"Lung Cancer"},{"key":"7802_CR10","first-page":"4527","volume":"35","author":"M Maehara","year":"2015","unstructured":"Maehara M, Ueda T, Miyahara D, Takahashi Y, Miyata K, Nam SO, et al. Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin. Anticancer Res. 2015;35:4527\u201334.","journal-title":"Anticancer Res"},{"key":"7802_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bjc.2013.400","volume":"109","author":"M Tanioka","year":"2013","unstructured":"Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer. 2013;109:859\u201365. https:\/\/doi.org\/10.1038\/bjc.2013.400.","journal-title":"Br J Cancer"},{"key":"7802_CR12","doi-asserted-by":"publisher","unstructured":"Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. 21:491\u20137. https:\/\/doi.org\/10.1007\/s10147-015-0928-y.","DOI":"10.1007\/s10147-015-0928-y"},{"key":"7802_CR13","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00520-017-3679-7","volume":"25","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Shimokawa M, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, et al. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer. 2017;25:2707\u201314. https:\/\/doi.org\/10.1007\/s00520-017-3679-7.","journal-title":"Support Care Cancer"},{"key":"7802_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV study Group of Japan. Int J Clin Oncol. 2015;20:855\u201365. https:\/\/doi.org\/10.1007\/s10147-015-0786-7.","journal-title":"Int J Clin Oncol"},{"key":"7802_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40360-020-00445-y","volume":"21","author":"R Matsui","year":"2020","unstructured":"Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T, et al. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. BMC Pharmacol Toxicol. 2020;21:72. https:\/\/doi.org\/10.1186\/s40360-020-00445-y.","journal-title":"BMC Pharmacol Toxicol"},{"key":"7802_CR16","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","volume":"18","author":"PJ Hesketh","year":"2010","unstructured":"Hesketh PJ, Aapro M, Street JC. Carides AD (2010) evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010;18:1171\u20137. https:\/\/doi.org\/10.1007\/s00520-009-0737-9.","journal-title":"Support Care Cancer"},{"key":"7802_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","volume":"19","author":"DG Warr","year":"2011","unstructured":"Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. 2011;19:807\u201313. https:\/\/doi.org\/10.1007\/s00520-010-0899-5.","journal-title":"Support Care Cancer"},{"key":"7802_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","volume":"20","author":"DL Hilarius","year":"2012","unstructured":"Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 2012;20:107\u201317. https:\/\/doi.org\/10.1007\/s00520-010-1073-9.","journal-title":"Support Care Cancer"},{"key":"7802_CR19","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis registry (PEER). Ann Oncol. 2012;23:1986\u201392. https:\/\/doi.org\/10.1093\/annonc\/mds021.","journal-title":"Ann Oncol"},{"key":"7802_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/annonc\/mdl377","volume":"18","author":"Y Ohe","year":"2007","unstructured":"Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol. 2007;18:317\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdl377.","journal-title":"Ann Oncol"},{"key":"7802_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00280-017-3439-x","volume":"81","author":"R Sakurai","year":"2018","unstructured":"Sakurai R, Tomizawa Y, Yoshii A, et al. A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer. Cancer Chemother Pharmacol. 2018;81:103\u20139. https:\/\/doi.org\/10.1007\/s00280-017-3439-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7802_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1515725.","journal-title":"N Engl J Med"},{"key":"7802_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2019","unstructured":"Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;21:242\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3.","journal-title":"Lancet Oncol"},{"key":"7802_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","volume":"84","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Inui N, Karayama M, et al. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol. 2019;84:147\u201353. https:\/\/doi.org\/10.1007\/s00280-019-03868-5.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07802-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-07802-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07802-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T19:04:08Z","timestamp":1610737448000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-07802-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7802"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-07802-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board of Fukuoka University (H20\u201308-004). The datasets used for this study were provided by the principal investigators of studies A [] and B [].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}